These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 2966105

  • 1. Non-specific suppressor cells in murine bone marrow chimeras: their possible role in GVHD-associated immunodeficiency.
    Imamura M, Fujimoto H, Fukuhara T, Kobayashi M, Hashino S, Kasai M, Sakurada K, Miyazaki T.
    Immunobiology; 1988 Feb; 176(3):313-27. PubMed ID: 2966105
    [Abstract] [Full Text] [Related]

  • 2. [Alloreactivity and mitogen-induced responses in allogeneic murine bone marrow chimeras].
    Fujimoto H.
    Nihon Ketsueki Gakkai Zasshi; 1989 Aug; 52(5):858-68. PubMed ID: 2531528
    [Abstract] [Full Text] [Related]

  • 3. Suppressor cells detected in murine bone marrow chimeras.
    Imamura M.
    Jpn J Exp Med; 1986 Oct; 56(5):221-8. PubMed ID: 2949096
    [Abstract] [Full Text] [Related]

  • 4. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C, Allard A, Brochu S, Poupart C, Fontaine P, Bélanger R, Gyger M.
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [Abstract] [Full Text] [Related]

  • 5. FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B.
    Tao HR.
    Hokkaido Igaku Zasshi; 1998 May; 73(3):227-37. PubMed ID: 9719949
    [Abstract] [Full Text] [Related]

  • 6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 8. In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease.
    Imamura M, Hashino S, Kobayashi H, Tanaka J, Imai K, Han M, Fujii Y, Kobayashi M, Higa T, Kasai M.
    Immunobiology; 1994 Jun 15; 190(4-5):346-67. PubMed ID: 7982720
    [Abstract] [Full Text] [Related]

  • 9. [Hematopoietic reconstitution in the allogeneic bone marrow chimeric mice].
    Fukuhara T.
    Hokkaido Igaku Zasshi; 1988 Jul 15; 63(4):616-23. PubMed ID: 3065194
    [Abstract] [Full Text] [Related]

  • 10. Characterization studies of suppressor cells in murine bone marrow chimaeras.
    Imamura M, Fujimoto H, Fukuhara T, Kobayashi M, Kasai M, Sakurada K, Miyazaki T.
    Immunology; 1987 Jan 15; 60(1):29-36. PubMed ID: 2950049
    [Abstract] [Full Text] [Related]

  • 11. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 12. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
    Maier T, Holda JH, Claman HN.
    J Immunol; 1985 Sep 15; 135(3):1644-51. PubMed ID: 3160774
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The activity of suppressor cells in the spleen of murine bone marrow chimeras.
    Imamura M, Miyazaki T, Fujimoto H, Fukuhara T, Kasai M, Itaya T, Sakurada K.
    Transplantation; 1986 Nov 15; 42(5):548-55. PubMed ID: 2947357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD.
    Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoé K.
    Bone Marrow Transplant; 2000 Nov 15; 26(10):1069-76. PubMed ID: 11108305
    [Abstract] [Full Text] [Related]

  • 17. In vivo administration of cytokine in allogeneic bone marrow chimeras.
    Imamura M, Fujimoto H, Hashino S, Fukuhara T, Kobayashi M, Kasai M, Sakurada K, Miyazaki T.
    Immunobiology; 1990 Jun 15; 180(4-5):441-57. PubMed ID: 1697845
    [Abstract] [Full Text] [Related]

  • 18. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.
    Brok HP, Vossen JM, Heidt PJ.
    Bone Marrow Transplant; 1997 Mar 15; 19(6):601-6. PubMed ID: 9085739
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
    Sykes M, Eisenthal A, Sachs DH.
    J Immunol; 1988 May 01; 140(9):2903-11. PubMed ID: 2966200
    [Abstract] [Full Text] [Related]

  • 20. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 01; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.